Company: CDLX
Filing Date: 2025-03-12
Form Type: 10-K
Source: 0001666071-25-000034
Chunk: 113

Company: Cardlytics, Inc.
Filing Date: 2025-03-12
Form: 10-K
Item: Item 8
Chunk 113
---
643 28,248 30,403 Sales and marketing expense52,649 57,425 74,745 Research and development expense49,607 51,352 54,435 General and administrative expense56,482 58,810 81,446 Acquisition, integration and divestiture costs (benefits) 161 (6,313)(2,874)Change in contingent consideration210 1,246 (128,174)Impairment of goodwill and intangible assets131,595 70,518 453,288 Loss on divestiture— 6,550 — Depreciation and amortization expense25,689 26,460 37,544 Total costs and expenses473,797 444,874 756,320 Operating loss(195,499)(135,670)(457,778)Other income (expense):Interest expense, net(5,553)(2,336)(2,556)Foreign currency (loss) gain(1,269)3,304 (6,376)Gain on debt extinguishment13,017 — — Total other income (expense)6,195 968 (8,932)Loss before income taxes(189,304)(134,702)(466,710)Income tax benefit— — 1,446 Net Loss(189,304)(134,702)(465,264)Net loss per share, basic and diluted$(3.91)$(3.69)$(13.92)Weighted-average common shares outstanding, basic and diluted48,361 36,488 33,419 

See notes to the consolidated financial statements65

CARDLYTICS, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Amounts in thousands)

 Year Ended December 31, 202420232022Net Loss$(189,304)$(134,702)$(465,264)Other comprehensive loss:  Foreign currency translation adjustments1,134 (3,131)5,112 Total Comprehensive Loss$(188,170)$(137,833)$(460,152)

See notes to the consolidated financial statements66

CARDLYTICS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Amounts in thousands)

Year Ended December 31, 2024:

AdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncome (loss)Accumulated